Posted by Reuters: Business News on September 23, 2011
NEW YORK (Reuters) – The research chief of Roche Holding AG said the company’s experimental drug to raise “good” HDL cholesterol has the potential to generate annual sales of $10 billion and may have advantages over a rival medicine being developed by Merck & Co Inc .
Posted by Reuters: Business News on February 25, 2011
WASHINGTON (Reuters) – Health regulators want more data on Protalix Biotherapeutics Inc and Pfizer Inc’s experimental drug for Gaucher disease before deciding whether to approve the therapy for…
Posted by Reuters: Business News on June 7, 2010
NEW YORK/LONDON (Reuters) – Bristol-Myers Squibb Co’s shares rose more than 8 percent on Monday after news over the weekend that its experimental drug ipilimumab extended survival in patients with deadly skin cancer.
